jetcityimage / iStock Editorial via Getty Images Eli Lilly stock was up more than 50% in 2024, before declining in 2025.

Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.

The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY2025 guidance, and growing GLP-1 market share have been well negated by the underwhelming oral candidate results. NVO's upcoming oral candidate launch in late 2025/ early 2026 and potentially rich TAM of $23.75B by 2030 have also been derailed by the management change and lowered FY2025 guidance.

Kelowna, British Columbia –   TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization (“ CRO ”) has completed the important study milestone known as last patent last visit (“ LPLV ”) in Lexaria's Phase 1b glucagon-like peptide-1 (“ GLP-1 ”) study in Australia, GLP-1-H24-4 (the “ Study ”).   “We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study,” said John Docherty, Lexaria's President and CSO.  “Study work continues with full sample and data analyses currently underway in order to reach our late 2025 final reporting objective.”

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Global Partners (GLP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals. The news jolted the health care sector, which fell by 2.74% over the past five days, compounding its struggles this year, which have resulted in its 5.13% loss—the worst among all 11 sectors in the S&P 500.

Global Partners LP Common Units (NYSE:GLP ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Eric S. Slifka - President, CEO & Vice Chairman of Global GP LLC Gregory B.

Global Partners (GLP) Q2 EPS Falls 50%

In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch INDIANAPOLIS , Aug. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron, met the primary endpoint and all key secondary endpoints compared to placebo, delivering clinically meaningful weight loss as an adjunct to a healthy diet and physical activity.